Systemic administration of members of IGF axis was reported to improve glycemic control in T2DM patients [199] as well as insulin sensitivity and pancreatic β-cell functions [200] making IGF proteins promising candidates as therapeutic modalities for obesity, insulin resistance and diabetes [201,202]. The gene discussed is IGF1; the disease is Insulin resistance.